ClinicalTrials.gg
CompletedNCT05813795Updated Apr 30, 2025

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

A Phase 3 interventional study of Ecnoglutide Low Dosage and Ecnoglutide Medium Dosage in Weight Management, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's title name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
664
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..

Enrollment
Largest of 10
664 · median 152
Started
2023
the only one that year
Phase 3
5 of 10
4 open now
Registered
1st of 10
by date

Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one has the largest enrollment, is the only one that started in 2023, is one of 5 in phase 3, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., or all of them as a file.
02

Study summary

The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

Read the detailed description

In this Phase 3 study, eligible participants will be randomized into three cohorts in a 3:1:3:1:3:1 ratio to receive once-weekly subcutaneous XW003 (low, medium, or high dosage) or volume-matching placebo for 48 weeks, including a dose-escalation period.

03

Conditions studied

  • Weight Management

Browse trials for

Keywords

  • Weight management
  • overweight
  • obesity
  • glucagon-like peptide-1 (GLP-1)
  • ecnoglutide
  • XW003
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 664 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18-75 years old, inclusive;
  2. between 24.0 to 28.0 kg/m2 with at least one comorbidity, including prediabetes, hypertension, hyperlipidemia, fatty liver , obstructive sleep apnea syndrome, etc.; or BMI ≥ 28 kg/m2 with or without comorbidities.
  3. Weight change of no more than 5% (based on self-report), with diet and exercise alone, within 3 months before screening.
  4. Willing and able to maintain stable diet and exercise during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Obesity induced by endocrine diseases such as hypothyroidism, Cushing Syndrome, etc.
  2. History of bariatric surgery (except liposuction >1 year ago) or planned bariatric surgery during the study period.
  3. Within 3 months before screening, history of using the following drugs or treatments:

    1. Any approved or unapproved weight-loss drugs or Chinese herbs or health products that affect body weight.
    2. Any hypoglycemic medication.
    3. Any medication that may cause significant weight gain, including systemic treatment, tricyclic anti-depressants, anti-epileptic and antipsychotics.
    4. Any drug, vaccine, or medical device.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
664 participants (actual)

Study arms

  • Experimental
    C1- XW003 Low Dosage

    XW003 with low dosage once weekly

    Drug: Ecnoglutide Low Dosage

  • Placebo comparator
    C1-Placebo

    Matched Placebo once weekly

    Drug: Placebo

  • Experimental
    C2- XW003 Medium Dosage

    XW003 with medium dosage once weekly

    Drug: Ecnoglutide Medium Dosage

  • Placebo comparator
    C2-Placebo

    Matched Placebo once weekly

    Drug: Placebo

  • Experimental
    C3- XW003 High Dosage

    XW003 with high dosage once weekly

    Drug: Ecnoglutide High Dosage

  • Placebo comparator
    C3-Placebo

    Matched Placebo once weekly

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline

    Time frame: Week 40

  2. Proportion of subjects with weight loss ≥5% from baseline

    Time frame: Week 40

Secondary outcomes

  1. Percent and absolute body weight change from baseline

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48

  2. Proportion of subjects with weight loss ≥ 5%, 10%, 15% from baseline

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48

  3. Change from baseline in BMI

    height will be only measured at baseline

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48

  4. Change from baseline in waist and hip circumferences

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48

08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2024, 14 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 14 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 14, 2023
StartActual
Apr 5, 2023
Primary completionActual
Jun 20, 2024
CompletionActual
Oct 10, 2024
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05813795
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Apr 5, 2023
Primary completion
Jun 20, 2024
Completion
Oct 10, 2024
Last update
Apr 30, 2025

Study contacts

Linong Ji, Dr
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecnoglutide

Start the discussion